- Ages between 50 and 90 years old
- Have concerns about memory or been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease within the last year
Detailed eligibility will be reviewed with the study team.
The purpose of this prescreening study is to identify people that may be eligible for future clinical trials that test new drugs for Alzheimer’s disease.
The study visit consists of a short memory assessment and a blood draw. The blood sample will be analyzed to assess a participant’s general health, as well as to measure levels of a protein called pTau217, which is linked to Alzheimer’s disease. The test used to measure this protein, the Elecsys Phospho-Tau (217P) plasma test, is experimental, which means it has not been approved by the United States Food and Drug Administration (FDA) for diagnosing Alzheimer’s disease.
The study can last for up to 14 days. If the screening and baseline visit occur on the same day, then the study would only take 1 day.